Edwards Lifesciences Corp — Director's Dealing 2021

May 7, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Edwards Lifesciences Corp (EW)
CIK: 0001099800
Period of Report: 2021-05-04

Reporting Person: Ullem Scott B. (CVP, Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-05-04	Common Stock	A	5100.0000	$0.0000	Acquired	32214.0000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-05-04	Employee Stock Option (Right to Acquire)	$93.3100	A	44400.0000	Acquired	2028-05-03	Common Stock (44400.0000)	Direct
2021-05-04	Performance Rights	$	A	6375.0000	Acquired	2028-05-03	Common Stock (6375.0000)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	229251.0000	Indirect

Footnotes

F1: These restricted stock units were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F2: These options were granted on May 4, 2021 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments.

F3: Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 4, 2021 and scheduled to vest on May 4, 2024. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards.